ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[
This report contains market size and forecasts of Anaplastic Lymphoma Kinase Inhibitors in global, including the following market information:
Global Anaplastic Lymphoma Kinase Inhibitors Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Anaplastic Lymphoma Kinase Inhibitors Market Sales, 2017-2022, 2023-2028, (MT)
Global top five Anaplastic Lymphoma Kinase Inhibitors companies in 2021 (%)
The global Anaplastic Lymphoma Kinase Inhibitors market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Crizotinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anaplastic Lymphoma Kinase Inhibitors include Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd. and Xcovery Holding Company, LLC and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Anaplastic Lymphoma Kinase Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anaplastic Lymphoma Kinase Inhibitors Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, by Type, 2021 (%)
Crizotinib
Ceritinib
Alectinib Hydrochloride
Global Anaplastic Lymphoma Kinase Inhibitors Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, by Application, 2021 (%)
NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others
Global Anaplastic Lymphoma Kinase Inhibitors Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (MT)
Global Anaplastic Lymphoma Kinase Inhibitors Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anaplastic Lymphoma Kinase Inhibitors revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Anaplastic Lymphoma Kinase Inhibitors revenues share in global market, 2021 (%)
Key companies Anaplastic Lymphoma Kinase Inhibitors sales in global market, 2017-2022 (Estimated), (MT)
Key companies Anaplastic Lymphoma Kinase Inhibitors sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Betta Pharmaceutcials Co., Ltd.
Crtierium, Inc.
F.Hoffman-La Roche Ltd.
Helsinn Therapeutics
Novartis AG.
Oncoethix GmbH
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Xcovery Holding Company, LLC
Tesaro, Inc.